Navigation Links
Commercial Insight: Antihormonal Cancer Therapies - Leading Brands Strive to Minimize Generic Sales Erosion
Date:11/8/2010

impact of generic erosion, losing around 25% of its value over the forecast period 12

The aromatase inhibitors will continue to be the leading drug class in 2019 13

The current leading antihormonal brands will suffer generic sales erosion but will maintain a high level of sales 14

The antihormonal therapies market will shrink from $7.0 billion in 2009 to $6.5 billion in 2019 across the seven major pharmaceutical markets 15

Opportunities and threats 17

Opportunity 1: aging population will result in increasing cancer incidence 17

Opportunity 2: oncology therapy sales continue to experience strong growth 18

Opportunity 3: high levels of unmet need 19

Threat 1: Pharma's transition towards specialist secondary care indications may further competition in the oncology market 20

Threat 2: the cost of drug development continues to rise 20

Threat 3: ongoing cost-containment measures 20

US 21

Current and future market assessment 21

The US antihormonals market will suffer the greatest impact of generic sales erosion 21

Opportunities and threats 25

Opportunity 1: the US's large population and high healthcare expenditure will continue to offer commercial opportunities for drug developers 25

Opportunity 2: healthcare reform will boost the number of insured in the US 25

Opportunity 3: closure of the Medicare Part D coverage gap is good news for branded Pharma 26

Threat 1: growing regulatory pressures increase costs and decrease market penetration for Pharma 26

Threat 2: patent expiries and the resulting generic competition will erode branded sales revenues 27

Threat 3: the US health reform law will intensify cost-containment pressures 27

Japan 28

Current and future market assessment 28

The antihormonals market in Japan is forecast to grow over the forecast period 28

Opportunities and threats 32

Opportunity 1:
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic Gastrointestinal Cancers Represent a Significant Commercial Opportunity Due to a Lack of Approved Drugs
2. GSK and Amicus Therapeutics Enter Exclusive Worldwide Agreement to Develop and Commercialize Amigal™ for Fabry Disease
3. Amicus Therapeutics to Host Conference Call and Webcast to Discuss Exclusive Worldwide Agreement with GSK to Develop and Commercialize Amigal™ for Fabry Disease
4. High Unemployment Rates in North Carolina Will Continue to Dictate the Decrease of Commercial Health Plan Enrollment and the Increase of Medicaid Enrollment
5. Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics
6. Reportlinker Adds Commercializing Cancer Vaccines: A Decision Support Tool for Optimizing the Pipeline
7. Biocon and Pfizer Enter Into Global Commercialization Agreement
8. TaiGen Amends Global License Agreement with Warner Chilcott plc for Development and Commercialization of Nemonoxacin -- a New Generation Quinolone Antibiotic
9. OLIGOMERIX, Inc. Announces Board Changes: Vic Micati Appointed Chairman and Jack Pasini Appointed Company Director and Chief Commercial Officer
10. IRIDEX Announces Commercial Availability of New Adjustable & Intuitive EndoProbe® Device for Eye Surgery
11. Concentric Medical Announces Commercial Launch of Trevo™ in Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014   Reproductive Medicine ... leader in the field of infertility, presents new ... embryonic screening. The research abstract, released during the ... Medicine (ASRM) meeting in Honolulu, Hawaii ... single gene defect (SGD) pre-implantation genetic diagnosis (PGD). ...
(Date:10/22/2014)... October 22, 2014 A new ... Market (Product type, Form, End user, Application and Geography) ... Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - ... market. Based on key trends tracked, it is anticipated ... $7.9 billion by 2020, registering a CAGR of 6.2% ...
(Date:10/22/2014)...   BioNano Genomics , the genome mapping ... to purchase an Irys™ System . Among them ... (NCI), NIH Intramural Sequencing Center (NISC) and Genoscope (The ... comprehensive view of a genome was a major ... deliver the scalability or reliability to detect and ...
Breaking Medicine Technology:New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 2New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 3Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 2Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 3Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 4BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 3
(Date:10/25/2014)... 2014 The proposed consolidation of all ... in December, when the U.S. Judicial Panel on Multidistrict ... a Hearing Session Order issued by the Panel on ... heard on December 4, 2014, in Charleston, South Carolina. ... Re: Xarelto Products Liability Litigation, No. 2592) , “Our ...
(Date:10/25/2014)... Background: , In 1998 Bob Savage founded the ... in the field of establishing recovery community organizations. Bob ... when he retired, he set out to answer a couple ... , 1. Where are the people in recovery ... 2. Can the recovery community be organized to advocate for ...
(Date:10/25/2014)... October 25, 2014 QueenBeeTickets.com has a ... great selection at affordable prices. Bob Seger & The ... Center and Nationwide Arena are going on sale October ... Click Here to browse the selection of tickets ... QueenBeeTickets.com. , The famous singer is touring North America ...
(Date:10/25/2014)... (PRWEB) October 25, 2014 Limbkeepers® announced ... episode of Innovations with Ed Begley Jr, airing 1st ... TBA. , In this episode, Innovations will focus on ... to protect fragile, thinning skin on arms, hands, and ... learn about these versatile products, which help reduce injuries, ...
(Date:10/25/2014)... Researchers who discovered antibiotics in farmed and wild ... The use of antibiotics in animals, including ... to the development of antibiotic-resistant bacteria that threaten ... study. Each year in the United States, ... kill about 23,000, according to the Infectious Diseases ...
Breaking Medicine News(10 mins):Health News:Xarelto Lawsuit News: JPML to Hear Oral Arguments on Proposed Xarelto Multidistrict Litigation at December Hearing, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit News: JPML to Hear Oral Arguments on Proposed Xarelto Multidistrict Litigation at December Hearing, Bernstein Liebhard LLP Reports 3Health News:CCAR Accepting Nominations for the Bob Savage Recovery Advocate of the Year Award 2Health News:QueenBeeTickets.com Features Bob Seger & The Silver Bullet Band Tickets for Charleston Civic Center, Huntington Center, and Nationwide Arena at Reduced Prices 2Health News:Upcoming Episode of Innovations with Ed Begley, Jr. to Feature Limbkeepers® 2Health News:Researchers Say Antibiotics in Fish a Health Concern 2
... Cosmecueticals, beauty aids that reportedly work like prescription drugs, ... study recently published in the Journal of Cosmetic Dermatology ... provide a visibly noticeable improvement in maturing skin. , ... the lack of skin surface regularity, formation of wrinkles, ...
... 28 Versus,Technology, Inc. ("Versus" or the "Company") ... October 31, 2007, compared to,revenues of $2,177,000 for ... year,ended October 31, 2007, were $5,566,000 compared to ... vary significantly depending on,the timing and delivery of ...
... MB Software,Corporation (OTC Bulletin Board: MBSB) announced ... Equity Partners to issue 490.196 shares of its,Series ... cancellation of,approximately $1,500,000 in debt. The debt was ... affiliates. The preferred stock will,automatically convert into an ...
... gadolinium-containing contrast injections in adults and pediatric patients (those ... to a recent study conducted by researchers at the ... these reactions do occur, most of them are mild, ... study. , Over the past few years, the ...
... Dec. 28 /PRNewswire-FirstCall/ - AlphaRx Inc. (OTC BB:ALRX,- ... for Drug Delivery,Platforms, announce that in order to ... directors, consultants and employees plan to,exercise stock options ... Lee, President and CEO, will cancel 6,000,000 options,granted ...
... 28 Lincare Holdings,Inc. (Nasdaq: LNCR ) today ... and Exchange Commission (the "SEC") a resale shelf registration,statement ... pursuant to the terms,of a registration rights agreement Lincare ... sale of its $275 million principal amount of,convertible senior ...
Cached Medicine News:Health News:Versus Technology Announces Fourth Quarter Results 2Health News:Versus Technology Announces Fourth Quarter Results 3Health News:Versus Technology Announces Fourth Quarter Results 4Health News:Versus Technology Announces Fourth Quarter Results 5Health News:Versus Technology Announces Fourth Quarter Results 6Health News:Versus Technology Announces Fourth Quarter Results 7Health News:MB Software Corporation Reaches Agreement with Keystone Equity Partners 2Health News:Allergic reactions to gadolinium-based contrast agents are rare, study finds 2Health News:AlphaRx Officers and Directors To Exercise Options, Warrants and Retain Shares 2Health News:Lincare Holdings Inc. Reports Intention to File Shelf Registration Statement 2
... including the Ceralas D and SmilePro 980 ... medical, dental, and veterinary environments.,With unsurpassed, optimal ... nm laser series allow controlled tissue ablation ... surgical procedures. Unlike other medical lasers, biolitecs ...
... Assay is a second generation nucleic acid ... in vitro qualitative detection and differentiation of ... uses a family of Gen-Probe's proven technologies ... and Dual Kinetic Assay (DKA). This is ...
... The InTray™ GC is a ... detection of both Neisseria gonorrhoeae and ... a long shelf life and is ... system. Simply inoculate, incubate and ...
... designed for patients with a spherical hyperopia between ... who would benefit from a spherical treatment of ... a myopic endpoint of between -1.00 D and ... improve near vision. CK is unique in that ...
Medicine Products: